Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv mecarbil modified-release dose-escalation and expansion study in systolic heart failure
NL-OMON39652Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omecamtiv mecarbil in heart failure (HF) and left ventricular systolic dysfunction (LVSD) (4 arms), sponsored by Amgen. Started Apr 2014; status: active, not recruiting.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NL-OMON39652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39652.